The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1316
ISSUE1316
July 13, 2009
Golimumab (Simponi) for Inflammatory Arthritis
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Golimumab (Simponi) for Inflammatory Arthritis
July 13, 2009 (Issue: 1316)
Golimumab (Simponi - Centocor), a fully humanized anti-tumor necrosis factor (TNF)-a antibody, has been approved by the FDA for the treatment of: (1) moderate to severe active rheumatoid arthritis (RA) in combination with methotrexate; (2) active...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.